Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (12132)	6/28/2013 3:46:44 PM
From: Howard Williams	Read Replies (1) \| Respond to of 13111

>>Say, speaking of the faux doubter, where was NTTG at the share holders meeting, considering he works just a few miles away from where it was held? One would imagine the the great NTTG would have the perfect opportunity to hold managements feet to the fire or have answers to all his questions and doubts personally. << Double thumbs up, Mimbari. PS The attendee also mentioned that RB's use combatting staph, strep and MRSA also came up. That hadn't been mentioned in a while as I recall.

To: Mimbari who wrote (12132)	6/28/2013 4:56:57 PM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (1) \| Respond to of 13111

Narrow approval is always understood to be a within disease state description, as in "PV-10 will not be studied further for aggressive stage III or stage IV patients, only non aggressive stage III disease.....hence they will only be able to actively promote drug use for non-aggressive stage III patients" (Actually, this point has been a matter of public record for some time, a bit surprised you reacted to that statement?). This is in marked contrast to other drugs in late stage development, or recently approved, that are looking at both stage III and stage IV disease. You have confused the companies misnomer about 'broad spectrum' activity for RB...a hold over from Dee's former ID days where antibiotics are described as having 'narrow' or 'broad' spectrum activity depending on their ability to kill Gram positive, Gram negative and/or atypical pathogens. Simple stuff